"New Jersey Hematology Oncology Associates (NJHOA) was founded in Brick, NJ by Dr. Amin in 1996. As our practice grew there was a need for another associate, Dr. Pavlak-Schenk joined the practice in 2000. NJHOA expanded its practice to Southern Ocean County and in 2005 they opened an additional office in Toms River, NJ. Dr. Agrawal joined NJHOA in 2011. Currently, all of our physicians have admitting and consulting privileges at: Ocean Medical Center, Jersey Shore University Medical Center, Community Medical Center, and Kimball Medical Center."

During the past decade, New Jersey Center for Cancer Research conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "New Jersey Center for Cancer Research" #1 sponsor was "Loxo Oncology, Inc." with 2 trials, followed by "Blue Note Therapeutics" with 1 trials sponsored, "Hangzhou Zenshine Pharmaceuticals Co., Ltd." with 1 trials sponsored, "Innovent Biologics (Suzhou) Co. Ltd." with 1 trials sponsored and "MediMergent, LLC" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "New Jersey Center for Cancer Research" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Amgen" with 1 trials as a collaborator and "Sanofi" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "New Jersey Center for Cancer Research" are "Chronic Lymphocytic Leukemia" (4 trials), "Small Lymphocytic Lymphoma" (4 trials), "Acute Myeloid Leukemia" (1 trials), "Anatomic Stage I Breast Cancer AJCC v8" (1 trials) and "Anatomic Stage II Breast Cancer AJCC v8" (1 trials). Many other conditions were trialed in "New Jersey Center for Cancer Research" in a lesser frequency.

Most popular intervention types in "New Jersey Center for Cancer Research" are "Drug" (7 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Azacitidine" (2 trials), "Bendamustine" (2 trials), "Rituximab" (2 trials), "Attune™" (1 trials) and "Cerena™" (1 trials). Other intervention names were less common.

The vast majority of trials in "New Jersey Center for Cancer Research" are 8 trials for "All" genders.

Currently, there are NaN active trials in "New Jersey Center for Cancer Research". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in New Jersey Center for Cancer Research, 1 suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in New Jersey Center for Cancer Research, 3 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".